TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00698802
Drug: EX1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target titration scheme, s.c. injection
Study: NCT01100320
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 40-mg tablet x 1 dose taken with food
Study: NCT01100320
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
Study: NCT00003519
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04428151
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
Study: NCT02728089
Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Study: NCT04083365
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
Study: NCT00782717
Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
Study: NCT00782717
Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED)
Normalized name: prednisolone acetate Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
Study: NCT01596751
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
Study: NCT02446717
Drug: ABT-493, ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)
Study: NCT02446717
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT01191086
Drug: USL255
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00541749
Drug: rhuMAb IFNalpha
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00893373
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AML chemotherapy plus placebo
Study: NCT01420718
Drug: iRoot BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
Study: NCT00550407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily
Study: NCT00774293
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
Study: NCT00774293
Drug: Arnica and Bryonia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
Study: NCT01236521
Drug: Pharmacological (MED)
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment.
Study: NCT00398658
Drug: gentamycin and clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04203836
Drug: LEO 152020 Tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: film-coated tablet
Study: NCT01908452
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg/d during 12 weeks
Study: NCT03946748
Drug: REGN3918
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
Study: NCT02515734
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02515734
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03216408
Drug: Neuronox
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00596167
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
Study: NCT03829917
Drug: Miltefosine and Paromomycin
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days of miltefosine plus 28 days of Paromomycin cream
Study: NCT03829917
Drug: paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days of paromomycin creaam
Study: NCT01367548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05399394
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
Study: NCT01738802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will take a placebo.
Study: NCT00478335
Drug: hydrochlorothiazide/amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
Study: NCT00478335
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight
Study: NCT00478335
Drug: placebo for calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: one nasal spray daily
Study: NCT03009006
Drug: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
Study: NCT03009006
Drug: Calcium Hydroxide Paste - Non-Setting
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
Study: NCT00444613
Drug: E0302 (mecobalamin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
Study: NCT00444613
Drug: E0302 (mecobalamin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
Study: NCT00444613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, placebo twice a week for 3.5 years.
Study: NCT03971409
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00937846
Drug: GSK1034702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 5 mg dose in liquid formulation
Study: NCT00540202
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken twice daily for 3 days according to weight based guidelines.
Study: NCT01028040
Drug: AZD3043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, single dose
Study: NCT01028040
Drug: AZD3043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, single dose
Study: NCT04057040
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT04057040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02925195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205762
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stratum I
Study: NCT02205762
Drug: INDOMETHACIN
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
Study: NCT02205762
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fixed dose weekly orally for total treatment duration of 24 months.
Study: NCT02178540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose (4 capsules) of placebo
Study: NCT02783196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
Study: NCT03178994
Drug: Hydrophilic Cream
Normalized name: HYDROPHILIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic cream (in-house preparation) applies twice daily
Study: NCT00199589
Drug: Botulinic toxin (Botox)
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
Study: NCT01546090
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules were filled with starch
Study: NCT00365638
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00982033
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo qd for 24 weeks
Study: NCT01830010
Drug: Study Part 1: KRP203
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive KRP203 for 111 days
Study: NCT00751803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01830010
Drug: Study Part 2: KRP203 lower dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01830010
Drug: Study Part 2: KRP203 higher dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00117572
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
Study: NCT01555736
Drug: grass (80%) and rye (20%) pollens allergoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
Study: NCT03650036
Drug: Pulp Therapy CTZ Paste
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
Study: NCT00702806
Drug: Puregon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Puregon® 150 IU
Study: NCT00702806
Drug: Orgalutran®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Orgalutran® 0.25 mg
Study: NCT00702806
Drug: Pregnyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Pregnyl® 10,000 IU
Study: NCT03650036
Drug: Pulp Therapy ZOE Paste
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
Study: NCT00878306
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 62.5 mg daily x3 days, then 250 mg daily x3 days
Study: NCT00878306
Drug: Disulfiram + Efavirenz
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study: NCT04627155
Drug: LY03003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine,extended-release microspheres
Study: NCT01726530
Drug: transdermal fentanyl patch (50 mcg/hour)
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01726530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00878306
Drug: Disulfiram + Atazanavir
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study: NCT00878306
Drug: Disulfiram + Ritonavir
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study: NCT02187900
Drug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
Study: NCT01219699
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Study: NCT00476827
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
Study: NCT02163824
Drug: KPI-121 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT02163824
Drug: KPI-121 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT02163824
Drug: Vehicle of KPI-121 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study: NCT02163824
Drug: Vehicle of KPI-121 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study: NCT00855465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tid orally for 16 weeks
Study: NCT00466440
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose, then po QD until unblinding
Study: NCT03977116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will receive placebo therapy after catheter ablation.
Study: NCT03489317
Drug: Simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study: NCT01335165
Drug: ALXN1102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ascending Dose IV
Study: NCT01335165
Drug: ALXN1103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ascending Dose IV or SC
Study: NCT01925482
Drug: 6%CO2, 25%O2, balance N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT01925482
Drug: 6% CO2, 0%O2, balance N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT01925482
Drug: 20%CO2, 6%O2, balance N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT01925482
Drug: 0%CO2, 6%O2, balance N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT00568542
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 I.E. kg body weight placebo to erythropoetin beta
Study: NCT01135615
Drug: calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium acetate (1000 mg) 1 tablet three times a day
Study: NCT01925482
Drug: 6% CO2, 6%O2, balance N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT01925482
Drug: 6%CO2, 6%O2, 0%N2, balance argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure of middle ear to gas
Study: NCT02805439
Drug: S47445 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study: NCT02805439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study: NCT02774291
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01392768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
Study: NCT00537459
Drug: 16448
Normalized name: BARRIER,OSTOMY,NEW IMAGE H#16408
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01553591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets twice daily
Study: NCT03959345
Drug: Standard therapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Study: NCT03649139
Drug: Placebo drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual placebo drops
Study: NCT02768571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- saline 100 ml/day \* 21 days with rehabilitation
Study: NCT03872232
Drug: Ezetimibe/Rosuvastatin
Normalized name: EZETIMIBE/ROSUVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT01464229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01366599
Drug: HEC or MEC
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any HEC or MEC, including aprepitant
Study: NCT04484870
Drug: oral Danshu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
Study: NCT00531882
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg once a day
Study: NCT00531882
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
Study: NCT01494350
Drug: WR 279,396 topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
Study: NCT01361646
Drug: LC350189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study: NCT00918177
Drug: AP09004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00918177
Drug: Carbidopa/Levodopa, immediate release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03018691
Drug: OPA-15406
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03018691
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03196986
Drug: mil60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
Study: NCT01308086
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles